See today's BioWorld
To read the full story, subscribe or sign in.

Amicus, GSK Extend Their Fabry Disease Collaboration

July 19, 2012
By Marie Powers
Amicus Therapeutics Inc. strengthened ties with partner GlaxoSmithKline plc to develop and commercialize its lead compound, the chaperone migalastat HC1 (Amigal), in Fabry disease.
BioWorld